Conference
550 POSTER Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors
Authors
Duran I; Hotte S; Chen E; Hirte H; MacLean M; Turner S; Pond G; Wright J; Dancey J; Siu L
Volume
4
Publisher
Elsevier
Publication Date
November 2006
DOI
10.1016/s1359-6349(06)70555-9
Conference proceedings
European Journal of Cancer Supplements
Issue
12
ISSN
1359-6349